Scarica l'app Stockscreener
96.00
0.37%
-0.36
Dopo l'orario di chiusura:
96.00
Precedente Chiudi:
$96.36
Aprire:
$96.435
Volume 24 ore:
794.09K
Relative Volume:
0.86
Capitalizzazione di mercato:
$5.49B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-32.43
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
-2.54%
1M Prestazione:
-0.83%
6M Prestazione:
-40.45%
1 anno Prestazione:
-23.37%
Intervallo 1D:
$95.93
$96.83
Intervallo di 1 settimana:
$95.34
$100.33
Portata 52W:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
96.00 | 5.51B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
What analysts say about Glaukos Corporation stockPowerful market insights - Autocar Professional
Is Glaukos Corporation a good long term investmentFree Consultation - Autocar Professional
Why We're Not Concerned About Glaukos Corporation's (NYSE:GKOS) Share Price - 富途牛牛
Glaukos Corporation Stock Analysis and ForecastExceptional market positioning - jammulinksnews.com
What drives Glaukos Corporation stock priceFree Daily Trading Room Entry - Autocar Professional
What analysts say about Glaukos Corporation stock outlookFree Insider Trading Tips - beatles.ru
Midday Stock Roundup: loanDepot Shoots Up 16% - Orange County Business Journal
September 19th Options Now Available For Glaukos (GKOS) - Nasdaq
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $117 - 富途牛牛
(GKOS) Investment Report - news.stocktradersdaily.com
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - simplywall.st
BTIG Increases Glaukos (GKOS) Price Target Ahead of Q2 Results | - GuruFocus
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 - BioSpace
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks - Yahoo Finance
Glaukos to Release Second Quarter 2025 Financial Results after M - GuruFocus
Press Release: Glaukos to Release Second Quarter 2025 Financial Results After Market Close on July 30 - 富途牛牛
Glaukos Prepares for New Product Launches - Orange County Business Journal
Glaukos Corporation(NYSE: GKOS) added to Russell 2000 Defensive Index - MarketScreener
Glaukos gains EU certification for iStent infinite and other MIGS devices - Yahoo Finance
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies - BioSpace
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies | GKOS Stock News - GuruFocus
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell | GKOS Stock News - GuruFocus
Trend Tracker for (GKOS) - news.stocktradersdaily.com
Glaukos Receives EU Regulatory Certification for Devices and Technologies to Treat Glaucoma - 富途牛牛
Glaukos Corporation: Delivering Consistent Growth (NYSE:GKOS) - Seeking Alpha
Glaukos Trades Higher Than Medical Peers NYSE Composite - Kalkine Media
What Makes Glaukos (GKOS) a New Buy Stock - Yahoo Finance
Trading (GKOS) With Integrated Risk Controls - news.stocktradersdaily.com
Piper Sandler names Abbott, Edwards, Glaukos as top medtech catalyst picks - Investing.com Canada
Glaukos Corp (GKOS) Shares Up 6.05% on Jun 11 - GuruFocus
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect? - sharewise
Here’s Why Glaukos (GKOS) Shares Traded Lower in Q1 - Insider Monkey
Stifel maintains buy rating on Glaukos stock, $115 target unchanged By Investing.com - Investing.com India
Glaukos at Jefferies Conference: Eyeing Interventional Success By Investing.com - Investing.com South Africa
Glaukos at Jefferies Conference: Eyeing Interventional Success - Investing.com
Stifel maintains buy rating on Glaukos stock, $115 target unchanged - Investing.com
Glaukos at William Blair Conference: Eyeing Innovative Growth By Investing.com - Investing.com South Africa
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):